BRAF and melanoma: A further study of 142 advanced melanoma patients (70 receiving BRAF/MEKi and 72 receiving ICIs) found that baseline ctDNA was detectable in 56% of cases, with declining ctDNA within 12 weeks strongly associated with better outcomes (p < 0.001 for PFS, p < 0.05 for OS) [123].